IL276117B1 - Modulating the expression of SLAMF6 variants for cancer treatment - Google Patents

Modulating the expression of SLAMF6 variants for cancer treatment

Info

Publication number
IL276117B1
IL276117B1 IL276117A IL27611720A IL276117B1 IL 276117 B1 IL276117 B1 IL 276117B1 IL 276117 A IL276117 A IL 276117A IL 27611720 A IL27611720 A IL 27611720A IL 276117 B1 IL276117 B1 IL 276117B1
Authority
IL
Israel
Prior art keywords
slamf6
modulation
cancer therapy
splice variants
splice
Prior art date
Application number
IL276117A
Other languages
English (en)
Hebrew (he)
Other versions
IL276117A (en
Inventor
Lotem Michal
Eisenberg Galit
Hajaj Emma
Original Assignee
Hadasit Med Res Service
Lotem Michal
Eisenberg Galit
Hajaj Emma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Lotem Michal, Eisenberg Galit, Hajaj Emma filed Critical Hadasit Med Res Service
Publication of IL276117A publication Critical patent/IL276117A/en
Publication of IL276117B1 publication Critical patent/IL276117B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL276117A 2018-02-12 2019-02-11 Modulating the expression of SLAMF6 variants for cancer treatment IL276117B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862629129P 2018-02-12 2018-02-12
PCT/IL2019/050163 WO2019155474A1 (en) 2018-02-12 2019-02-11 Modulation of slamf6 splice variants for cancer therapy

Publications (2)

Publication Number Publication Date
IL276117A IL276117A (en) 2020-08-31
IL276117B1 true IL276117B1 (en) 2026-04-01

Family

ID=67548888

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276117A IL276117B1 (en) 2018-02-12 2019-02-11 Modulating the expression of SLAMF6 variants for cancer treatment

Country Status (5)

Country Link
US (1) US11834487B2 (https=)
EP (1) EP3752252A4 (https=)
JP (1) JP7458318B2 (https=)
IL (1) IL276117B1 (https=)
WO (1) WO2019155474A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN117867107A (zh) * 2023-11-24 2024-04-12 南通大学附属医院 一种构建肠癌诊断和预后相关的甲基化位点的诊断模型方法及其诊断标志物slamf6

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104711A1 (en) * 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
CA2454185A1 (en) 2001-07-19 2003-01-30 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
JP2005206478A (ja) 2004-01-20 2005-08-04 Kirin Brewery Co Ltd 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物
WO2005124346A1 (en) 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
EP1916302A4 (en) 2005-08-17 2009-10-21 Takara Bio Inc PROCESS FOR THE PRODUCTION OF LYMPHOCYTES
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US7847067B2 (en) 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN105431449B (zh) 2013-04-05 2021-08-24 港大科桥有限公司 新的pd1同种型及其用于加强免疫应答的用途
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104711A1 (en) * 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI [ONLINE]. 04 NOVEMBER 2016 (04/11/2016)., SUBNAME: PREDICTED: GORILLA GORILLA GORILLA SLAM FAMILY MEMBER 6 (SLAMF6), TRANSCRIPT VARIANT X3, MRNA., 4 November 2016 (2016-11-04) *
DATABASE UNIPROT [ONLINE]., SUBNAME: FULL=CDNA FLJ52047, HIGHLY SIMILAR TO SLAM FAMILY MEMBER 6 {ECM:0000313|EMBL:BAG64907.1};, 23 September 2008 (2008-09-23) *
EISENBERG, GALIT, ET AL., SOLUBLE SLAMF6 RECEPTOR INDUCES STRONG CD8+ T-CELL EFFECTOR FUNCTION AND IMPROVES ANTI-MELANOMA ACTIVITY IN VIVO., 31 January 2018 (2018-01-31) *

Also Published As

Publication number Publication date
IL276117A (en) 2020-08-31
US11834487B2 (en) 2023-12-05
EP3752252A1 (en) 2020-12-23
WO2019155474A1 (en) 2019-08-15
US20210054043A1 (en) 2021-02-25
JP7458318B2 (ja) 2024-03-29
JP2021516668A (ja) 2021-07-08
EP3752252A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
IL288522A (en) Inhibitor of egfr for cancer treatment
IL267795A (en) Combined treatment for cancer
EP3307240A4 (en) Combination therapy for the treatment of cancer
EP4010081A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
ZA202206743B (en) Therapy for the treatment of cancer
SG11202011117VA (en) Treatment of cancer
EP3781215A4 (en) Methods of treating cancer
EP3796891A4 (en) THERAPEUTIC CONSTRUCTS FOR TREATMENT OF CANCER
IL282093A (en) Combination therapy for cancer
EP3897649A4 (en) COMBINED TREATMENT OF SOLID CANCERS
EP3860610A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
IL289201A (en) Compounds for the treatment of cancer
IL266993A (en) Combined therapy for cancer treatment
IL284162A (en) Integrated healing for cancer treatment
IL276117A (en) Modulating expression of slamf6 variants for cancer therapy
IL279591A (en) Cancer treatment methods using combination therapy
GB201820098D0 (en) Methods of cancer treatment
SG11202109025XA (en) Combinations of iadademstat for cancer therapy
GB201918815D0 (en) Treatment of cancer
GB201820975D0 (en) Methods of cancer treatment
IL253642A0 (en) Combined treatment for cancer
HK40069796A (en) Combinations of iadademstat for cancer therapy
HK40061708A (en) Combination therapy for the treatment of cancer
HK40060019A (en) Combination therapy for the treatment of cancer
HK40054682A (en) Combination therapy for treating cancer